Evidence map›Paper›PMID 34607834›Full record

SynthesisDiabetes care2021

Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas.

Adem Y Dawed, Sook Wah Yee, Kaixin Zhou, Nienke van Leeuwen, Yanfei Zhang, Moneeza K Siddiqui, Amy Etheridge, Federico Innocenti, Fei Xu, Josephine H Li and 19 more

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Common genetic variants nearmedRxiv : the preprint server for health sciences · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. A novel splice-affectingThe Lancet regional health. Europe · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 9 institutions in 4 countries.

Adem Y DawedPopulation Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K.ORCID 0000-0003-0224-2428
Sook Wah YeeDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA.
Kaixin ZhouPopulation Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K.
Nienke van LeeuwenDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
Yanfei ZhangGenomic Medicine Institute, Geisinger, Danville, PA.
Moneeza K SiddiquiPopulation Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K.ORCID 0000-0001-9055-3896
Amy EtheridgeDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Federico InnocentiDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Fei XuDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
Josephine H LiDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Joline W BeulensAmsterdam UMC, location VUmc, Department of General Practice, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.
Amber A van der HeijdenAmsterdam UMC, location VUmc, Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.
Roderick C SliekerDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
Yu-Chuan ChangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA.
Josep M MercaderDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Varinderpal KaurDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
John S WitteDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
Ming Ta Michael LeeGenomic Medicine Institute, Geisinger, Danville, PA.
Yoichiro KamataniRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Yukihide MomozawaRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Michiaki KuboRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Colin N A PalmerPopulation Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K.
Jose C FlorezDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Monique M HeddersonDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
Leen M 't HartDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
Kathleen M GiacominiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA.
Ewan R PearsonORCID 0000-0001-9237-8585
for MetGen Plus, for the DIRECT Consortium
MetGen Plus investigators:
University of California, San Francisco · USUniversity of Dundee · GBBroad Institute · USLeiden University Medical Center · NLRIKEN Center for Integrative Medical Sciences · JPAmsterdam University Medical Centers · NLUniversity Medical Center Utrecht · NLUniversity of North Carolina at Chapel Hill · USKaiser Permanente · US

Funding

TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETEST32DK007028 · MASSACHUSETTS GENERAL HOSPITAL · 1986 to 2025
$4.2M
NIDDK NIH HHS K24 DK110550NIDDK NIH HHS P30 DK098722NIDDK NIH HHS R01 DK088214NIDDK NIH HHS T32 DK007028NIGMS NIH HHS R01 GM117163Wellcome TrustWellcome Trust 102820/Z/13/Z
6 · The paper itself

Abstract

objectiveSulfonylureas, the first available drugs for the management of type 2 diabetes, remain widely prescribed today. However, there exists significant variability in glycemic response to treatment. We aimed to establish heritability of sulfonylurea response and identify genetic variants and interacting treatments associated with HbA RESEARCH DESIGN AND

methodsAs an initiative of the Metformin Genetics Plus Consortium (MetGen Plus) and the DIabetes REsearCh on patient straTification (DIRECT) consortium, 5,485 White Europeans with type 2 diabetes treated with sulfonylureas were recruited from six referral centers in Europe and North America. We first estimated heritability using the generalized restricted maximum likelihood approach and then undertook genome-wide association studies of glycemic response to sulfonylureas measured as HbA

resultsAfter establishing that sulfonylurea response is heritable (mean ± SEM 37 ± 11%), we identified two independent loci near the

conclusionsWe have identified clinically important genetic effects at genome-wide levels of significance, and important drug-drug-gene interactions, which include commonly prescribed statins. With increasing availability of genetic data embedded in clinical records these findings will be important in prescribing glucose-lowering drugs.

Indexed as

Diabetes Mellitus, Type 2MetforminBlood GlucoseGenome-Wide Association StudyGlycated HemoglobinHumansHypoglycemic AgentsLikelihood FunctionsLiver-Specific Organic Anion Transporter 1Sulfonylurea CompoundsBlood GlucoseGlycated HemoglobinHypoglycemic AgentsLiver-Specific Organic Anion Transporter 1MetforminSLCO1B1 protein, humanSulfonylurea Compounds

Identifiers

PMID34607834
PMCPMC8669535
OpenAlexW3203518968

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.